The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita
Cells · 2025
DOI: 10.3390/cells14211661 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Markus Thieme und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Allergy, and Venereology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. Hauptthemen laut MEDLINE: Tetrahydronaphthalenes, Epidermolysis Bullosa Acquisita, Pemphigoid, Bullous, Benzoates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Tamibarotene (AM80) is an agonist of retinoic acid receptor alpha. It is licensed in Japan for the treatment of acute promyelocytic leukemia. Results from preclinical models suggest that tamibarotene might also be effective in the treatment of diverse autoimmune diseases. The effect of tamibarotene on autoimmune diseases of the skin, however, has not been explored. We therefore examined the effect of tamibarotene on disease in the antibody-transfer mouse model of bullous pemphigoid (BP)-like epidermolysis bullosa acquisita (EBA), a prototypical example for pemphigoid diseases. Pemphigoid diseases are a group of autoimmune blistering skin diseases driven by autoantibodies and the recruitment and activity of granulocytes in the dermis. In sharp contrast to its effect in models of other autoimmune diseases, tamibarotene aggravated EBA pronouncedly. At the peak of disease, skin inflammation in tamibarotene-treated mice involved, on average, 1.6-fold more of the total body surface compared to vehicle-treated mice. Tamibarotene markedly reduced the recruitment of regulatory T cells (Tregs) into the dermis. This blunted the counterregulatory mechanisms that normally curb skin inflammation in this model. The effect aligns with previous reports describing tamibarotene-mediated downregulation of skin-homing receptors on Tregs. In addition, tamibarotene prolonged the responsiveness of aging neutrophils to immune complexes in vitro, providing another mechanism that may exacerbate EBA. Collectively, our results suggest that tamibarotene may elicit detrimental effects in patients with EBA by abolishing the recruitment of Tregs into skin. This warrants great caution when using tamibarotene in patients with EBA and possibly other pemphigoid diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Allergy, and Venereology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.
- Department of Dermatology and Venereology, University of Rostock, Strempelstraße 13, 18057 Rostock, Germany.
- Department of Dermatology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
- Department of Dermatology and Allergy, Christian Albrechts University of Kiel, Chrisitan-Albrechts-Platz 4, 24118 Kiel, Germany.
ORCID-Profile: Markus Thieme, Paul Schilf, Christian D Sadik
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Thieme, M., Schilf, P., Murthy, S., Gonther, S., Hammers, C. M., Heine, G., & Sadik, C. D. (2025). The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita. Cells. https://doi.org/10.3390/cells14211661
Vancouver
Thieme M, Schilf P, Murthy S, Gonther S, Hammers CM, Heine G, et al. The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita. Cells. 2025. doi:10.3390/cells14211661
BibTeX
@article{Thieme2025,
author = {Thieme, Markus and Schilf, Paul and Murthy, Sripriya and Gonther, Sina and Hammers, Christoph M and Heine, Guido and Sadik, Christian D},
title = {The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14211661}
}
EUVIMED